These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

763 related items for PubMed ID: 25805938

  • 1. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES, Song GA, Cho KB, Park KS, Kim KO, Jang BI, Kim EY, Jeon SW, Lee HS, Yang CH, Lee YK, Lee DW, Kim SK, Kim TO, Lee J, Kim HW, Jee SR, Park SJ, Kim HJ.
    World J Gastroenterol; 2015 Mar 21; 21(11):3308-16. PubMed ID: 25805938
    [Abstract] [Full Text] [Related]

  • 2. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F, Lubrano E, Marchesoni A, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Spadaro A.
    Int J Rheum Dis; 2016 Aug 21; 19(8):799-805. PubMed ID: 26172207
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH.
    J Gastroenterol Hepatol; 2010 Nov 21; 25(11):1732-8. PubMed ID: 21039834
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW, Hong Y, Jung YJ, Yoo B, Lee CK, Kim YG, Yang SK, Byeon JS, Kim KJ, Ye BD, Lee SD, Kim WS, Kim DS, Shim TS.
    Respir Med; 2013 Nov 21; 107(11):1797-802. PubMed ID: 24029000
    [Abstract] [Full Text] [Related]

  • 7. Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.
    Kang J, Jeong DH, Han M, Yang SK, Byeon JS, Ye BD, Park SH, Hwang SW, Shim TS, Jo KW.
    J Korean Med Sci; 2018 Nov 19; 33(47):e292. PubMed ID: 30450023
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
    George LA, Gadani A, Cross RK, Jambaulikar G, Ghazi LJ.
    Dig Dis Sci; 2015 Nov 19; 60(11):3424-30. PubMed ID: 26115749
    [Abstract] [Full Text] [Related]

  • 10. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM, Lee HH, Lee BI, Lee KM, Eun SH, Cho ML, Kim JS, Park JM, Cho YS, Lee IS, Kim SW, Choi H, Choi MG.
    Aliment Pharmacol Ther; 2018 Jul 19; 48(2):196-205. PubMed ID: 29869804
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
    Thiebault H, Boyard-Lasselin P, Guignant C, Guillaume N, Wacrenier A, Sabbagh C, Rebibo L, Brazier F, Meynier J, Nguyen-Khac E, Dupas JL, Goëb V, Fumery M.
    Eur J Gastroenterol Hepatol; 2016 Aug 19; 28(8):876-81. PubMed ID: 27101404
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease.
    Kurti Z, Lovasz BD, Gecse KB, Balint A, Farkas K, Morocza-Szabo A, Gyurcsanyi A, Kristof K, Vegh Z, Gonczi L, Kiss LS, Golovics PA, Lakatos L, Molnar T, Lakatos PL.
    J Gastrointestin Liver Dis; 2015 Dec 19; 24(4):467-72. PubMed ID: 26697573
    [Abstract] [Full Text] [Related]

  • 17. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea.
    Lee JY, Oh K, Hong HS, Kim K, Hong SW, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Lee HS, Jo KW, Park SH.
    BMC Gastroenterol; 2021 Oct 20; 21(1):390. PubMed ID: 34670529
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ.
    Expert Rev Gastroenterol Hepatol; 2015 Oct 20; 9 Suppl 1():35-44. PubMed ID: 26395533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.